About SpringWorks Therapeutics
SpringWorks Therapeutics is a company based in New York (United States) founded in 2017 was acquired by Merck in April 2025.. SpringWorks Therapeutics has raised $229.6 million across 4 funding rounds from investors including Pfizer, Merck and Citadel. SpringWorks Therapeutics offers products and services including Nirogacestat and Mirdametinib. SpringWorks Therapeutics operates in a competitive market with competitors including QSAM Biosciences, Vuja De Sciences, ECM Therapeutics, Atlanthera and Taithera, among others.
- Headquarter New York, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Springworks Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SpringWorks Therapeutics
SpringWorks Therapeutics offers a comprehensive portfolio of products and services, including Nirogacestat and Mirdametinib. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Gamma secretase inhibitor for BCMA combinations in multiple myeloma.
Treatment for NF1-PN in pediatric and adult patients.
Unlock access to complete
Unlock access to complete
Leadership Team
28 people
Software Development Team
28 people
Sales and Marketing
14 people
Operations Team
12 people
Human Resources and Administration
5 people
Finance and Accounting
4 people
Legal and Compliance
4 people
Senior Team
3 people
Unlock access to complete
Funding Insights of SpringWorks Therapeutics
SpringWorks Therapeutics has successfully raised a total of $229.6M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $225 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $225.0M
-
First Round
First Round
(25 Sep 2017)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Post-IPO - SpringWorks Therapeutics | Valuation |
investors |
|
| Apr, 2019 | Amount | Series B - SpringWorks Therapeutics | Valuation | Perceptive Advisors | |
| Dec, 2017 | Amount | Series A - SpringWorks Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SpringWorks Therapeutics
SpringWorks Therapeutics has secured backing from 18 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Merck and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SpringWorks Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SpringWorks Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Springworks Therapeutics Comparisons
Competitors of SpringWorks Therapeutics
SpringWorks Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QSAM Biosciences, Vuja De Sciences, ECM Therapeutics, Atlanthera and Taithera, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation
|
|
| domain | founded_year | HQ Location |
Therapies for preventing cancer metastasis and recurrence are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic and therapeutic products from extracellular matrix are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for bone diseases and tumors are developed.
|
|
| domain | founded_year | HQ Location |
Nanomedicine platform for targeted bone drug delivery is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Springworks Therapeutics
Frequently Asked Questions about SpringWorks Therapeutics
When was SpringWorks Therapeutics founded?
SpringWorks Therapeutics was founded in 2017.
Where is SpringWorks Therapeutics located?
SpringWorks Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Who is the current CEO of SpringWorks Therapeutics?
Saqib Islam is the current CEO of SpringWorks Therapeutics.
Is SpringWorks Therapeutics a funded company?
SpringWorks Therapeutics is a funded company, having raised a total of $229.6M across 4 funding rounds to date. The company's 1st funding round was a Series A of $1.6M, raised on Sep 25, 2017.
What does SpringWorks Therapeutics do?
Founded in 2017 and based in New York, United States, small molecule therapeutics are developed by SpringWorks Therapeutics within the biotechnology sector for cancer and rare diseases. Operations focus on advancing candidates such as Nirogacestat, a gamma-secretase inhibitor targeting desmoid tumors, a MEK 12 inhibitor for neurofibromatosis type 1, and senicapoc for hereditary xerocytosis involving dehydrated red blood cells.
Who are the top competitors of SpringWorks Therapeutics?
SpringWorks Therapeutics's top competitors include Vuja De Sciences, QSAM Biosciences and Taithera.
What products or services does SpringWorks Therapeutics offer?
SpringWorks Therapeutics offers Nirogacestat and Mirdametinib.